Shenzhou Cell Engineering's 'Bevacizumab' Applied for Listing
On April 22, China Cell Engineering's "bevacizumab" biosimilar drug was declared for listing.
Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and blocks its biological activity, reducing tumor angiogenesis, thereby inhibiting tumor growth. This is a veritable blockbuster drug. The original research came from Roche, and its peak sales exceeded 7 billion US dollars. However, in recent years, sales have declined due to the impact of similar drugs.
Bevacizumab is the most competitive biosimilar drug in China, and 9 products, including the original drug, have been approved for marketing, from Innovent Bio, Fuhong Henlius, Qilu Pharmaceutical, Hengrui Medicine, Boan Biology, TOT BIOPHARM, Bio-Otai. Before the listing of Shenzhou Cell Engineering News today, Chia Tai Tianqing has also submitted a listing application, and 9 more models are in Phase III clinical trials.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
Recommend Reading
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
October Petrocoke Prices Continue to Rise
-
Chemours Partners with SRF Limited to Enhance Fluoropolymer and Intermediates Portfolio
-
October China Soda Ash Market Trend Consolidates
-
Albéa Acquires Amfora Packaging, Strengthening Its Position in Latin America
-
Symrise Opens New Production Unit in Granada to Ensure Safer Supply of Bio-Based Pentylene Glycol